Solara Active Pharma Sciences Limited (SOLARA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Solara Active Pharma Sciences Limited ₹145, price ₹715, upside -79.8%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Solara Active Pharma Sciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹297.85 – ₹1,775 · fair‑value band ₹83.79 – ₹210.26 · the ₹714.85 price screens above the ₹144.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Solara Active Pharma Sciences in your weekly email
Every Wednesday you see whether Solara Active Pharma Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
Show more
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
Stock analysis
Solara Active Pharma Sciences Limited (SOLARA) currently trades at ₹714.85, while our model-based Fair Value estimate is ₹144.76, 79.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹295.35 per share, and 0 of the 13 models we run sit above the ₹714.85 price.
Bear case: the Earnings-Based group reads lowest at ₹69.81, and 13 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹83.79 (bear) to ₹210.26 (bull), the price of ₹714.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Solara Active Pharma Sciences Limited reported revenue of ₹13.7B in FY2026 versus ₹12.7B in FY2022, a compound +1.9%/yr. Reported net income was −₹74.1M in FY2026.
Key figures
Market cap ₹35.0B (≈ $363M) · P/S ratio 2.45 · EPS (TTM) ₹−0.6700 · Net margin −0.5% · Return on equity −0.6% · Return on assets (EBIT) 1.3% · Operating margin 9.2% · Revenue (TTM) ₹14.3B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −80%, SOLARA screens richer than that median.
Fair Value models
Bear ₹83.79Fair Value ₹144.76Bull ₹210.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.4% (2021) → 6.4% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Compare Solara Active Pharma Sciences Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 583 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−79.7% · Bottom 25%
Profitability
Return on assets2.4% · Below median
Net margin (TTM)−0.1% · Below median
Operating margin (TTM)9.2% · Below median
Growth and dividend
Revenue growth19.6% · Top 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/S (TTM)0.03× · Cheapest 25%
P/FCF4.1× · Cheapest 25%
EV/EBITDA0.5× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)98· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)96· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Solara Active Pharma Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/SOLARA
Frequently asked questions
Is Solara Active Pharma Sciences Limited (SOLARA) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹144.76 versus a price of ₹714.85, about −80% upside (overvalued).
What is the fair value of SOLARA?
Our model-based fair value for Solara Active Pharma Sciences Limited is ₹144.76 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹714.85.
What is the quality score of SOLARA?
Solara Active Pharma Sciences Limited has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Solara Active Pharma Sciences Limited (SOLARA)?
Our model-based price target is the fair value of ₹144.76 (as of Oct 1, 2026) from 13 valuation models. Cautious scenario ₹83.79, optimistic scenario ₹210.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Solara Active Pharma Sciences Limited stock forecast for 2026?
Our models put fair value at ₹144.76, about −80% upside versus a price of ₹714.85 (overvalued). Cautious scenario ₹83.79, optimistic scenario ₹210.26. The calculation is refreshed regularly with new filings.
What is the revenue of Solara Active Pharma Sciences Limited (SOLARA)?
Solara Active Pharma Sciences Limited reported trailing-twelve-month revenue of about ₹14.3B (latest available figure, as of Oct 1, 2026).
What growth is priced into Solara Active Pharma Sciences Limited (SOLARA)?
For today's price to be fair in a discounted-cash-flow model, Solara Active Pharma Sciences Limited would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -3.0 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of SOLARA use?
Our models discount Solara Active Pharma Sciences Limited at 13.6 %: a base by market capitalisation (small), damped by beta 0.92, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Solara Active Pharma Sciences Limited that is more than 80 % per year a year over ten years, using the same discount rate (13.6 %) and the same formula as our fair value.
How much growth has Solara Active Pharma Sciences Limited (SOLARA) delivered so far?
Over the past 5 years revenue at Solara Active Pharma Sciences Limited grew -3.0 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Solara Active Pharma Sciences Limited (SOLARA) growing?
The median revenue growth in the sector is +4.8 % a year. That is the yardstick for the growth priced into Solara Active Pharma Sciences Limited (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Solara Active Pharma Sciences Limited (SOLARA)?
The free-cash-flow yield on the price is 0.28 %: that much free cash flow Solara Active Pharma Sciences Limited produces per unit of market value. When it exceeds the discount rate of our models (13.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Solara Active Pharma Sciences Limited (SOLARA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Solara Active Pharma Sciences Limited it is ₹144.76 per share (as of Oct 1, 2026), against a price of ₹714.85. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Solara Active Pharma Sciences Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, SOLARA trades above its calculated fair value: price ₹714.85, fair value ₹144.76, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOLARA?
No. The price is what the market pays today (₹714.85); the fair value is what the company's own numbers justify (₹144.76). For Solara Active Pharma Sciences Limited the two are ₹570.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Solara Active Pharma Sciences Limited worth?
The market values Solara Active Pharma Sciences Limited at about ₹35.0B (market capitalisation, as of Oct 1, 2026). Per share that is ₹714.85; our models calculate a fair value of ₹144.76 per share.
What do the bullish and bearish scenarios say about SOLARA?
Our models span a range for Solara Active Pharma Sciences Limited: cautious scenario ₹83.79, base ₹144.76, optimistic ₹210.26 per share (as of Oct 1, 2026, price ₹714.85). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Solara Active Pharma Sciences Limited (SOLARA)?
Balance-sheet figures for Solara Active Pharma Sciences Limited (as of Oct 1, 2026): return on equity −0.6%, debt of 0.09 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is SOLARA from its 52-week high?
Solara Active Pharma Sciences Limited trades at ₹714.85, about 5% below its 52-week high of ₹753.25 and 68% above the low of ₹425.55 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹144.76 is for.
Which stocks are comparable to Solara Active Pharma Sciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Solara Active Pharma Sciences Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹714.85, calculated fair value ₹144.76 (−80%), Quality Score 33/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOLARA calculated?
We run Solara Active Pharma Sciences Limited through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹144.76, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Solara Active Pharma Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Solara Active Pharma Sciences Limited (SOLARA)?
The closing price on Oct 1, 2026 was ₹714.85. Our model-based fair value is ₹144.76, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Solara Active Pharma Sciences Limited right now?
The price sits above even our optimistic bull case (₹210.26). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (₹83.79 to ₹210.26) leaves room in how you read the outcome.
Key figures of Solara Active Pharma Sciences Limited
How large is the market capitalisation of Solara Active Pharma Sciences Limited (SOLARA)?
The market capitalisation of Solara Active Pharma Sciences Limited is ₹35.0B (≈ $363M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Solara Active Pharma Sciences Limited (SOLARA)?
The price-to-sales ratio of Solara Active Pharma Sciences Limited is 2.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Solara Active Pharma Sciences Limited (SOLARA)?
Earnings per share at Solara Active Pharma Sciences Limited are ₹−0.6700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Solara Active Pharma Sciences Limited (SOLARA)?
The net margin of Solara Active Pharma Sciences Limited is −0.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Solara Active Pharma Sciences Limited (SOLARA)?
The return on equity (ROE) of Solara Active Pharma Sciences Limited is −0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Solara Active Pharma Sciences Limited (SOLARA)?
On an EBIT basis the return on assets of Solara Active Pharma Sciences Limited is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Solara Active Pharma Sciences Limited (SOLARA)?
The operating margin of Solara Active Pharma Sciences Limited is 9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Solara Active Pharma Sciences Limited (SOLARA)?
Revenue at Solara Active Pharma Sciences Limited is growing +19.6% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Solara Active Pharma Sciences Limited (SOLARA)?
Earnings per share at Solara Active Pharma Sciences Limited are growing +43.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Solara Active Pharma Sciences Limited (SOLARA) carry?
The net debt of Solara Active Pharma Sciences Limited is ₹6.4B (fiscal year 2026, ≈ 71.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Solara Active Pharma Sciences Limited in the live analysis
One click puts Solara Active Pharma Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
